Gufic Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Şu anda Gufic Biosciences için büyüme ve gelir tahmini yapmak üzere yeterli analist kapsamımız yok.

Anahtar bilgiler

n/a

Kazanç büyüme oranı

n/a

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi	17.9%
Gelir büyüme oranı	n/a
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	None
Son güncelleme	n/a

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

There's Reason For Concern Over Gufic Biosciences Limited's (NSE:GUFICBIO) Massive 26% Price Jump

Nov 07

We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Jun 06

Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?

Jun 17

These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well

Sep 02

Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?

May 07

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Dec 07

This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid

Sep 15

Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?

Aug 12

Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest

Jun 11

If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late

Mar 19

What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?

Mar 01

Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like

Dec 01

Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet

Nov 13

The Gufic Biosciences (NSE:GUFICBIO) Share Price Has Gained 116%, So Why Not Pay It Some Attention?

Oct 19

Can Gufic Biosciences Limited's (NSE:GUFICBIO) ROE Continue To Surpass The Industry Average?

Sep 14

I Built A List Of Growing Companies And Gufic Biosciences (NSE:GUFICBIO) Made The Cut

Aug 24

Investors Appear Satisfied With Gufic Biosciences Limited's (NSE:GUFICBIO) Prospects

Aug 03

Earnings Tell The Story For Gufic Biosciences Limited (NSE:GUFICBIO)

Jul 09

Bu bölümde, yatırımcıların şirketin kâr elde etme kabiliyetini anlamalarına yardımcı olmak için genellikle profesyonel analistlerin fikir birliği tahminlerine dayanan gelir ve kazanç büyüme tahminlerini sunuyoruz. Ancak Gufic Biosciences yeterli geçmiş veri sağlamadığından ve analist tahmini olmadığından, gelecekteki kazançları geçmiş verileri ekstrapole ederek veya analist tahminlerini kullanarak güvenilir bir şekilde hesaplanamaz.

SimplyWall St tarafından kapsanan şirketlerin %97'si geçmiş finansal verilere sahip olduğu için bu oldukça nadir bir durumdur.

Kazanç ve Gelir Büyüme Tahminleri

NSEI:GUFICBIO - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (INR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
9/30/2024	8,038	849	-246	697	N/A
6/30/2024	8,145	864	N/A	N/A	N/A
3/31/2024	8,067	861	-1,202	-75	N/A
12/31/2023	7,847	842	N/A	N/A	N/A
9/30/2023	7,604	823	-1,639	159	N/A
6/30/2023	7,204	793	N/A	N/A	N/A
3/31/2023	6,906	797	-2,142	-266	N/A
12/31/2022	6,798	819	N/A	N/A	N/A
9/30/2022	6,744	826	-1,652	-355	N/A
6/30/2022	6,937	857	N/A	N/A	N/A
3/31/2022	7,792	958	188	1,062	N/A
12/31/2021	7,489	884	N/A	N/A	N/A
9/30/2021	7,434	829	1,662	1,798	N/A
6/30/2021	6,777	769	N/A	N/A	N/A
3/31/2021	4,877	442	749	873	N/A
12/31/2020	4,005	305	N/A	N/A	N/A
9/30/2020	3,538	243	-14	511	N/A
6/30/2020	3,195	123	N/A	N/A	N/A
3/31/2020	3,788	227	73	471	N/A
12/31/2019	3,681	243	N/A	N/A	N/A
9/30/2019	3,580	232	4	254	N/A
6/30/2019	3,640	249	N/A	N/A	N/A
3/31/2019	3,508	219	-79	52	N/A
12/31/2018	3,334	164	N/A	N/A	N/A
9/30/2018	3,353	168	N/A	N/A	N/A
6/30/2018	3,192	164	N/A	N/A	N/A
3/31/2018	3,056	165	N/A	-48	N/A
12/31/2017	2,887	181	N/A	N/A	N/A
9/30/2017	2,651	154	N/A	N/A	N/A
6/30/2017	2,544	124	N/A	N/A	N/A
3/31/2017	2,455	90	N/A	-41	N/A
12/31/2016	2,419	105	N/A	N/A	N/A
9/30/2016	2,329	98	N/A	N/A	N/A
6/30/2016	2,201	88	N/A	N/A	N/A
3/31/2016	2,022	73	N/A	-43	N/A
12/31/2015	1,806	62	N/A	N/A	N/A
9/30/2015	1,588	45	N/A	N/A	N/A
6/30/2015	1,500	36	N/A	N/A	N/A
3/31/2015	1,516	42	N/A	112	N/A
12/31/2014	1,533	43	N/A	N/A	N/A
9/30/2014	1,503	47	N/A	N/A	N/A
6/30/2014	1,366	47	N/A	N/A	N/A
3/31/2014	1,230	43	N/A	109	N/A
12/31/2013	1,104	37	N/A	N/A	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: GUFICBIO 'un tahmini kazanç büyümesinin tasarruf oranının ( 6.7% ) üzerinde olup olmadığını belirlemek için yeterli veri yok.

Kazançlar ve Piyasa: GUFICBIO 'un kazançlarının Indian pazarından daha hızlı büyümesinin öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Yüksek Büyüme Kazançları: GUFICBIO şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artıp artmayacağını belirlemek için yeterli veri bulunmuyor.

Gelir ve Pazar: GUFICBIO şirketinin gelirinin Indian pazarından daha hızlı büyüyeceğinin tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Yüksek Büyüme Geliri: GUFICBIO şirketinin gelirinin yıllık 20% oranından daha hızlı artacağının tahmin edilip edilmediğini belirlemek için yeterli veri yok.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: GUFICBIO 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Gufic Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Second quarter 2025 earnings released: EPS: ₹2.17 (vs ₹2.39 in 2Q 2024)

Gufic Biosciences Limited to Report Q2, 2025 Results on Nov 14, 2024

There's Reason For Concern Over Gufic Biosciences Limited's (NSE:GUFICBIO) Massive 26% Price Jump

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2024

Gufic Biosciences Limited Announces Cessation of Shreyas Patel as Independent Director and New Composition of Committees

Dividend of ₹0.10 announced

Gufic Biosciences Limited, Annual General Meeting, Sep 25, 2024

First quarter 2025 earnings released: EPS: ₹2.08 (vs ₹2.13 in 1Q 2024)

Gufic Biosciences Limited Announces Resignation of Bal Ram Singh as Non-Executive and Non-Independent Director

Gufic Biosciences Limited to Report Q1, 2025 Results on Aug 14, 2024

Gufic Biosciences Limited Announces Cessation of Rabi Sahoo as Independent Director and Chairman of Stakeholders Relationship Committee and Member of Audit Committee

Investor sentiment improves as stock rises 19%

We Think You Should Be Aware Of Some Concerning Factors In Gufic Biosciences' (NSE:GUFICBIO) Earnings

Gufic Biosciences Limited Proposes Recommendation of Final Dividend for the Financial Year 2023-24

Full year 2024 earnings released: EPS: ₹8.74 (vs ₹8.22 in FY 2023)

Third quarter 2024 earnings released: EPS: ₹2.23 (vs ₹2.10 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹2.39 (vs ₹2.09 in 2Q 2023)

Gufic Biosciences Limited announced that it has received INR 999.9 million in funding from Motilal Oswal Financial Services Limited

Upcoming dividend of ₹0.10 per share

Gufic Biosciences Limited to Report Q2, 2024 Results on Nov 14, 2023

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

New minor risk - Shareholder dilution

Gufic Biosciences Limited, Annual General Meeting, Sep 29, 2023

First quarter 2024 earnings released: EPS: ₹2.13 (vs ₹2.17 in 1Q 2023)

Gufic Biosciences Limited to Report Q1, 2024 Results on Aug 11, 2023

Is Gufic Biosciences (NSE:GUFICBIO) Using Too Much Debt?

Investor sentiment improves as stock rises 17%

Gufic Biosciences Limited Recommends Dividend for the Financial Year Ended March 31, 2023

Full year 2023 earnings released: EPS: ₹8.22 (vs ₹9.89 in FY 2022)

Third quarter 2023 earnings released: EPS: ₹2.10 (vs ₹2.17 in 3Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Second quarter 2023 earnings released: EPS: ₹2.09 (vs ₹2.41 in 2Q 2022)

Gufic Biosciences Limited Approves Final Dividend for the Financial Year Ended March 31, 2022

These 4 Measures Indicate That Gufic Biosciences (NSE:GUFICBIO) Is Using Debt Reasonably Well

Upcoming dividend of ₹0.10 per share

First quarter 2023 earnings released: EPS: ₹2.17 (vs ₹3.22 in 1Q 2022)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Gufic Biosciences Limited, Annual General Meeting, Sep 02, 2022

Gufic Biosciences Limited to Report Q1, 2023 Results on Aug 11, 2022

Investor sentiment improved over the past week

Gufic Biosciences Limited Launches New Drug Delivery System

Full year 2022 earnings released: EPS: ₹9.89 (vs ₹4.56 in FY 2021)

Gufic Biosciences Limited Proposes Final Dividend for the Financial Year Ended March 31, 2022

Should You Be Adding Gufic Biosciences (NSE:GUFICBIO) To Your Watchlist Today?

Now 21% undervalued

Gufic Biosciences Limited Receives Permission from CDSCO to Manufacture and Sale Isavuconazonium Sulfate API and Finished Formulation Isavuconazole for Injection 200 Mg/Vial

Now 21% undervalued

Gufic Biosciences Limited Receives DCGI Nod for Thymosin Alpha - 1

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Second quarter 2022 earnings released: EPS ₹2.41 (vs ₹2.10 in 2Q 2021)

This Is The Reason Why We Think Gufic Biosciences Limited's (NSE:GUFICBIO) CEO Might Be Underpaid

Upcoming dividend of ₹0.10 per share

Is Now The Time To Put Gufic Biosciences (NSE:GUFICBIO) On Your Watchlist?

Investor sentiment improved over the past week

Gufic Biosciences' (NSE:GUFICBIO) Performance Is Even Better Than Its Earnings Suggest

Full year 2021 earnings released: EPS ₹4.56 (vs ₹2.94 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

If You Like EPS Growth Then Check Out Gufic Biosciences (NSE:GUFICBIO) Before It's Too Late

What Percentage Of Gufic Biosciences Limited (NSE:GUFICBIO) Shares Do Insiders Own?

Gufic Biosciences (NSE:GUFICBIO) Has A Pretty Healthy Balance Sheet

Third quarter 2021 earnings released: EPS ₹1.69 (vs ₹0.90 in 3Q 2020)

Gufic Biosciences Limited to Report Q3, 2021 Results on Feb 08, 2021

Is Gufic Biosciences' (NSE:GUFICBIO) 164% Share Price Increase Well Justified?

Why Gufic Biosciences Limited (NSE:GUFICBIO) Looks Like A Quality Company

Investor sentiment improved over the past week

New 90-day high: ₹131

Here's Why I Think Gufic Biosciences (NSE:GUFICBIO) Is An Interesting Stock

Here's What Gufic Biosciences Limited's (NSE:GUFICBIO) Shareholder Ownership Structure Looks Like

Gufic Biosciences (NSE:GUFICBIO) Has A Somewhat Strained Balance Sheet